Press Releases
Information updates and press releases issued by Deep Genomics

Deep Genomics to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 6, 2022

TORONTO AND CAMBRIDGE, MA, January 6, 2022. Deep Genomics, the leading AI RNA therapeutics company, today announced that its Founder and CEO, Brendan Frey, PhD, FRSC, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 10 ...

Tal Zaks Joins Strategic Advisory Board at Deep Genomics

October 26, 2021


Former Moderna CMO and COVID-19 vaccine lead brings experience building hugely successful mRNA therapeutics company to Deep Genomics. 

TORONTO AND CAMBRIDGE, MA, October 26, 2021. Deep Genomics, the leading AI therapeutics company, welcomes Tal Zaks, M.D., Ph.D., to its Strategic Advisory Board, effective ...

Mila Announces Collaboration with Leading AI Therapeutics Company Deep Genomics

September 20, 2021

MONTREAL and TORONTO – September 20, 2021 – Mila, the Quebec Artificial Intelligence Institute, today announced the start of a partnership with Deep Genomics, a leading company in therapeutic artificial intelligence treatments. This collaboration will allow the company to join Mila's community and to take advantage ...

Deep Genomics Appoints Jeffrey M. Brown, Ph.D., Vice President of Preclinical Research

May 3, 2021


TORONTO – May 3, 2021. Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today the appointment of Jeffrey Brown, Ph.D., Vice President, Preclinical Research. Jeffrey will be responsible for advancing programs into IND-enabling studies, overseeing the discipline of experimental biology, and working with ...

BioMarin and Deep Genomics to Collaborate on Advancing Programs Identified Using Artificial Intelligence

November 17, 2020

 Deep Genomics

SAN RAFAEL and TORONTO, Nov. 17, 2020 — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Deep Genomics today announced that the companies have entered into a preclinical collaboration that will use Deep Genomics’ artificial intelligence drug discovery platform (The AI Workbench) to identify oligonucleotide drug candidates in ...

Amanda Kay Appointed Chief Business Officer of Deep Genomics, Tasked with Overseeing Expansion of Partnership Strategy

November 5, 2020

Company also announces appointment of Tom Hughes, Boston-based biotech builder and CEO of  Navitor Pharmaceuticals, to board of directors.
Company now advancing multiple programs in neurodevelopmental, neurodegenerative and  metabolic disorders.

TORONTO – November 5, 2020. Deep Genomics, the leading artificial intelligence (AI) therapeutics  company, announced today ...